Effects of Lysulin™ supplementation on pre-diabetes: study protocol for a randomized controlled trial
Autor: | John F Burd, Ranil Jayawardena, Lal Chandrasena, Vivianne Noetzel, Priyanga Ranasinghe |
---|---|
Rok vydání: | 2018 |
Předmět: |
Adult
medicine.medical_specialty Medicine (miscellaneous) Placebo law.invention Prediabetic State 03 medical and health sciences Study Protocol 0302 clinical medicine Randomized controlled trial Double-Blind Method law Internal medicine Diabetes mellitus medicine Humans Pharmacology (medical) 030212 general & internal medicine Vitamin C Exercise Glycemic Randomized Controlled Trials as Topic lcsh:R5-920 business.industry Clinical study design Lysine Middle Aged Micronutrient medicine.disease Clinical trial Zinc Lysulin™ Dietary Supplements Study Protocol Version Pre-diabetes lcsh:Medicine (General) business 030217 neurology & neurosurgery |
Zdroj: | Trials Trials, Vol 20, Iss 1, Pp 1-9 (2019) |
ISSN: | 1745-6215 |
Popis: | Background Diabetes mellitus is rapidly becoming one of the leading causes of morbidity and mortality worldwide. Preventive measures have become important, especially in the South Asian region and other parts of the world where diabetes is becoming increasingly prevalent. We postulate that a product containing amino acid lysine, micronutrient zinc and vitamin C will have beneficial effects on glycemic control and disease progression in patients with pre-diabetes and we aim to evaluate this hypothesis using a phase II/III randomized double-blind controlled clinical trial design. Methods/design The study will be conducted as a randomized, double-blind, placebo-controlled clinical trial for a period of 6 months. The study has been approved by the Ethics Review Committee of Faculty of Medicine, University of Colombo, Sri Lanka. A total of 110 adults with pre-diabetes will be recruited for the study. They will be randomly assigned to the test and placebo groups on a 1:1 ratio. The test group will receive two tablets of Lysulin™ three times a day and the control group will receive identical placebo tablets. The study drugs will be double blinded to both investigators and subjects. The visits and the evaluations will be done as follows: screening (visit 0), 1 month (visit 1), 3 months (visit 2) and 6 months (visit 4). The primary outcome will be defined as change in glycemic control measured by HbA1c from baseline. Data will be analyzed using SPSS v16. Discussion To our knowledge this is one of the first randomized controlled trials evaluating the effects of Lysulin™ (a combination of lysine, vitamin C and zinc) in pre-diabetes. This study will provide the necessary groundwork for future large-scale multicentered clinical trials. The result, positive or negative, should provide a step change in the evidence guiding current and future policies regarding management of pre-diabetes. Trial registration Sri Lanka Clinical Trials Registry, SLCTR/2018/022. Registered on 13 July 2018. Study protocol version 2.0 (23 March 2018). Electronic supplementary material The online version of this article (10.1186/s13063-019-3269-8) contains supplementary material, which is available to authorized users. |
Databáze: | OpenAIRE |
Externí odkaz: |